21 CFR 201, Subpart G - Specific Labeling Requirements for Specific Drug Products
- § 201.300 — Notice to manufacturers, packers, and distributors of glandular preparations.
- § 201.301 — Notice to manufacturers, packers, and distributors of estrogenic hormone preparations.
- § 201.302 — Notice to manufacturers, packers, and distributors of drugs for internal use which contain mineral oil.
- § 201.303 — Labeling of drug preparations containing significant proportions of wintergreen oil.
- § 201.304 — Tannic acid and barium enema preparations.
- § 201.305 — Isoproterenol inhalation preparations (pressurized aerosols, nebulizers, powders) for human use; warnings.
- § 201.306 — Potassium salt preparations intended for oral ingestion by man.
- § 201.307 — Sodium phosphates; package size limitation, warnings, and directions for over-the-counter sale.
- § 201.308 — Ipecac syrup; warnings and directions for use for over-the-counter sale.
- § 201.309 — Acetophenetidin (phenacetin)-containing preparations; necessary warning statement.
- § 201.310 — Phenindione; labeling of drug preparations intended for use by man.
- § 201.311 — [Reserved]
- § 201.312 — Magnesium sulfate heptahydrate; label declaration on drug products.
- § 201.313 — Estradiol labeling.
- § 201.314 — Labeling of drug preparations containing salicylates.
- § 201.315 — Over-the-counter drugs for minor sore throats; suggested warning.
- § 201.316 — Drugs with thyroid hormone activity for human use; required warning.
- § 201.317 — Digitalis and related cardiotonic drugs for human use in oral dosage forms; required warning.
- § 201.319 — Water-soluble gums, hydrophilic gums, and hydrophilic mucilloids (including, but not limited to agar, alginic acid, calcium polycarbophil, carboxymethylcellulose sodium, carrageenan, chondrus, glucomannan ((B-1,4 linked) polymannose acetate), guar gum, karaya gum, kelp, methylcellulose, plantago seed (psyllium), polycarbophil tragacanth, and xanthan gum) as active ingredients; required warnings and directions.
- § 201.320 — Warning statements for drug products containing or manufactured with chlorofluorocarbons or other ozone-depleting substances.
- § 201.323 — Aluminum in large and small volume parenterals used in total parenteral nutrition.
- § 201.325 — Over-the-counter drugs for vaginal contraceptive and spermicide use containing nonoxynol 9 as the active ingredient; required warnings and labeling information.
- § 201.326 — Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling.
- § 201.327 — Over-the-counter sunscreen drug products; required labeling based on effectiveness testing.
Title 21 published on 2012-04-01
The following are only the Rules published in the Federal Register after the published date of Title 21.
For a complete list of all Rules, Proposed Rules, and Notices view the Rulemaking tab.
This is a list of United States Code sections, Statutes at Large, Public Laws, and Presidential Documents, which provide rulemaking authority for this CFR Part.
This list is taken from the Parallel Table of Authorities and Rules provided by GPO [Government Printing Office].
It is not guaranteed to be accurate or up-to-date, though we do refresh the database weekly. More limitations on accuracy are described at the GPO site.
Title 21 published on 2012-04-01
The following are ALL rules, proposed rules, and notices (chronologically) published in the Federal Register relating to 21 CFR 201 after this date.
